Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 11 results
[
Author
]
Title
Type
Year
Filters:
Keyword
is
Antibodies, Monoclonal, Humanized
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
C
Cohen-Mekelburg S
,
Gold S
,
Schneider Y
,
Dennis M
,
Oromendia C
,
Yeo H
,
Michelassi F
,
Scherl E
,
Steinlauf A
. 2019.
Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.
.
Dig Dis Sci. 64(1):196-203.
D
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Battat R
,
Barsky M
,
Nguyen NH
,
Ma C
,
Narula N
,
Mosli M
,
Casteele NVande
,
Boland BS
,
Prokop L
et al.
. 2020.
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
.
Am J Gastroenterol. 115(6):885-894.
F
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
G
Gold SL
,
Magro C
,
Scherl E
. 2018.
A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.
.
Gastroenterology. 155(4):981-982.
L
Lukin DJ
,
Kumar A
,
Hajifathalian K
,
Sharaiha RZ
,
Scherl EJ
,
Longman RS
. 2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
.
Gastroenterology. 159(4):1541-1544.e2.
N
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
S
Sandborn WJ
,
Feagan BG
,
Fedorak RN
,
Scherl E
,
Fleisher MR
,
Katz S
,
Johanns J
,
Blank M
,
Rutgeerts P
. 2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
.
Gastroenterology. 135(4):1130-41.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
V
Verma HDev
,
Scherl EJanice
,
Jacob VElizabeth
,
Bosworth BPaul
. 2011.
Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
.
J Dig Dis. 12(5):379-83.
Y
Yang E
,
Panaccione N
,
Whitmire N
,
Dulai PS
,
Casteele NVande
,
Singh S
,
Boland BS
,
Collins A
,
Sandborn WJ
,
Panaccione R
et al.
. 2020.
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
.
Aliment Pharmacol Ther. 51(11):1031-1038.